Market Closed -
Nasdaq
03:59:47 2024-06-04 pm EDT
|
5-day change
|
1st Jan Change
|
3.65
USD
|
-0.54%
|
|
+3.11%
|
-2.41%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,479
|
7,933
|
5,587
|
980.4
|
368.8
|
416.6
|
-
|
-
|
Enterprise Value (EV)
1 |
1,258
|
7,450
|
4,971
|
544.2
|
53.6
|
187.4
|
263.8
|
277.1
|
P/E ratio
|
-13.6
x
|
-43.3
x
|
-26.1
x
|
-3.47
x
|
-2.28
x
|
-2.06
x
|
-2.05
x
|
-2.07
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
139
x
|
252
x
|
100
x
|
10.2
x
|
5.8
x
|
71.6
x
|
77.3
x
|
87.5
x
|
EV / Revenue
|
118
x
|
237
x
|
89
x
|
5.65
x
|
0.84
x
|
32.2
x
|
49
x
|
58.2
x
|
EV / EBITDA
|
-
|
-
|
-23.5
x
|
-1.85
x
|
-0.31
x
|
-0.95
x
|
-1.23
x
|
-1.24
x
|
EV / FCF
|
-13.9
x
|
-169
x
|
-23.3
x
|
-1.92
x
|
-0.39
x
|
-1.49
x
|
-1.52
x
|
-1.66
x
|
FCF Yield
|
-7.2%
|
-0.59%
|
-4.3%
|
-52.1%
|
-258%
|
-67.1%
|
-65.7%
|
-60.1%
|
Price to Book
|
-
|
-
|
8.25
x
|
2.03
x
|
0.98
x
|
1.58
x
|
1.51
x
|
2.44
x
|
Nbr of stocks (in thousands)
|
75,593
|
87,244
|
95,494
|
97,170
|
98,602
|
113,832
|
-
|
-
|
Reference price
2 |
19.57
|
90.93
|
58.51
|
10.09
|
3.740
|
3.660
|
3.660
|
3.660
|
Announcement Date
|
3/2/20
|
2/24/21
|
2/28/22
|
2/28/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
10.68
|
31.43
|
55.85
|
96.3
|
63.53
|
5.818
|
5.387
|
4.76
|
EBITDA
1 |
-
|
-
|
-211.1
|
-294.6
|
-172.2
|
-197.6
|
-213.7
|
-223.6
|
EBIT
1 |
-100.7
|
-128.1
|
-217
|
-308.4
|
-190.5
|
-211.4
|
-229.3
|
-241
|
Operating Margin
|
-943.14%
|
-407.47%
|
-388.56%
|
-320.23%
|
-299.86%
|
-3,632.55%
|
-4,256.49%
|
-5,062.93%
|
Earnings before Tax (EBT)
1 |
-98.15
|
-173.4
|
-212.2
|
-281.7
|
-160.9
|
-201
|
-224.2
|
-249.9
|
Net income
1 |
-98.15
|
-173.4
|
-212.2
|
-281.7
|
-160.9
|
-201.1
|
-224.2
|
-249.7
|
Net margin
|
-919%
|
-551.59%
|
-379.89%
|
-292.55%
|
-253.3%
|
-3,456.97%
|
-4,162.5%
|
-5,246.58%
|
EPS
2 |
-1.440
|
-2.100
|
-2.240
|
-2.910
|
-1.640
|
-1.777
|
-1.788
|
-1.767
|
Free Cash Flow
1 |
-90.57
|
-44.16
|
-213.6
|
-283.8
|
-138.4
|
-125.7
|
-173.3
|
-166.7
|
FCF margin
|
-848.03%
|
-140.49%
|
-382.43%
|
-294.68%
|
-217.86%
|
-2,159.84%
|
-3,217.82%
|
-3,501.4%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/2/20
|
2/24/21
|
2/28/22
|
2/28/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
17.07
|
18.41
|
18.55
|
14.98
|
44.36
|
58.98
|
0.933
|
1.944
|
1.676
|
1.925
|
1.548
|
1.24
|
1.31
|
1.404
|
1.404
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-43.19
|
-46.25
|
-47.9
|
-48.43
|
-48.97
|
-
|
-
|
EBIT
1 |
-69.38
|
-74.47
|
-83.11
|
-86.39
|
-64.42
|
-28.59
|
-62.56
|
-51.28
|
-48.08
|
-51.07
|
-51.99
|
-53.5
|
-54.11
|
-53.53
|
-56.01
|
Operating Margin
|
-406.48%
|
-404.4%
|
-448.05%
|
-576.67%
|
-145.23%
|
-48.48%
|
-6,705.79%
|
-2,637.81%
|
-2,868.44%
|
-2,652.88%
|
-3,358.5%
|
-4,313.13%
|
-4,131.46%
|
-3,814.09%
|
-3,990.88%
|
Earnings before Tax (EBT)
1 |
-68.62
|
-65.69
|
-76.1
|
-83.56
|
-56.36
|
-18.88
|
-52.76
|
-45.17
|
-44.12
|
-48
|
-49.54
|
-51.37
|
-52.16
|
-52.5
|
-55.12
|
Net income
1 |
-68.62
|
-65.69
|
-76.1
|
-83.56
|
-56.36
|
-18.88
|
-52.76
|
-45.17
|
-44.12
|
-48
|
-49.54
|
-51.35
|
-52.13
|
-52.43
|
-55.15
|
Net margin
|
-402.02%
|
-356.74%
|
-410.29%
|
-557.79%
|
-127.07%
|
-32.01%
|
-5,654.34%
|
-2,323.56%
|
-2,632.58%
|
-2,493.71%
|
-3,200.27%
|
-4,139.71%
|
-3,980.18%
|
-3,735.75%
|
-3,929.39%
|
EPS
2 |
-0.7200
|
-0.6800
|
-0.7800
|
-0.8600
|
-0.5800
|
-0.1900
|
-0.5400
|
-0.4600
|
-0.4500
|
-0.4700
|
-0.4583
|
-0.4700
|
-0.4575
|
-0.4612
|
-0.4712
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/4/22
|
8/3/22
|
11/3/22
|
2/28/23
|
5/3/23
|
8/8/23
|
11/8/23
|
2/26/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
221
|
483
|
616
|
436
|
315
|
229
|
153
|
140
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-90.6
|
-44.2
|
-214
|
-284
|
-138
|
-126
|
-173
|
-167
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-39.9%
|
-48.5%
|
-37.8%
|
-60.8%
|
-74.9%
|
-74.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
7.090
|
4.970
|
3.810
|
2.320
|
2.430
|
1.500
|
Cash Flow per Share
2 |
-
|
-
|
-1.720
|
-2.560
|
-1.340
|
-1.380
|
-0.9100
|
-
|
Capex
1 |
7.4
|
4.93
|
50.7
|
35.6
|
6.15
|
3.53
|
8.67
|
5.5
|
Capex / Sales
|
69.24%
|
15.69%
|
90.79%
|
36.93%
|
9.68%
|
60.73%
|
160.89%
|
115.55%
|
Announcement Date
|
3/2/20
|
2/24/21
|
2/28/22
|
2/28/23
|
2/26/24
|
-
|
-
|
-
|
Last Close Price
3.66
USD Average target price
6.643
USD Spread / Average Target +81.50% Consensus |
1st Jan change
|
Capi.
|
---|
| -2.41% | 417M | | +16.73% | 123B | | +13.04% | 107B | | -5.80% | 24.01B | | +1.69% | 22.59B | | -10.09% | 18.16B | | -40.52% | 16.84B | | -14.00% | 16.23B | | +1.18% | 13.43B | | +24.18% | 11.32B |
Bio Therapeutic Drugs
|